Clarissa Sowemimo-Coker
Chief Executive Officer at OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC
Net worth: 4 300 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Indraneil Mahapatra | M | 44 |
Oxford Cannabinoid Technologies Ltd.
 Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 7 years |
| Charanjit Dhillon | F | 66 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Julie Pomeroy | F | 69 | - | |
| Timothy Corn | M | 73 | 1 years | |
| Karen Lowe | F | 55 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| John Lucas | M | 58 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 3 years |
| Paul Smalley | M | - | 2 years | |
| Robin Bennett | M | - | 2 years | |
| Richard Hathaway | M | 57 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Bishrut Mukherjee | M | 37 |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
| Valentino Parravicini | M | 55 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hee-Dong Kim | M | - |
Oxford Cannabinoid Technologies Ltd.
Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Clarissa Sowemimo-Coker
- Personal Network
